Qualification of Molecular neuroimaging of the dopamine transporter as biomarker for to identify patients with early manifest Parkinsonism in Parkinson’s disease.
Qualification of Molecular neuroimaging of the dopamine transporter as biomarker for to identify patients with early manifest Parkinsonism in Parkinson’s disease.